Heuckmann, J. M., M. Hölzel, M. L. Sos, S. Heynck, H. Balke-Want, M. Koker, M. Peifer, J. Weiss, C. M. Lovly, C. Grütter, D. Rauh, W. Pao and R. K. Thomas: ALK mutations conferring differential resistance to structurally diverse ALK inhibitors. In: Clinical Cancer Research 17, 23, 7394-7401 (2011).
doi: 10.1158/1078-0432.CCR-11-1648
Peifer, M., J. Weiss, M. L. Sos, M. Koker, S. Heynck, C. Netzer, S. Fischer, H. Rode, D. Rauh, J. Rahnenführer and R. K. Thomas: Analysis of Compound Synergy in High-Throughput Cellular Screens by Population-Based Lifetime Modeling. In: PLoS ONE 5, 1, , Seq. No.: 1 (2010).
url: http://dx.doi.org/10.1371/journal.pone.0008919
Peifer, M., J. Weiss, M. L. Sos, M. Koker, S. Heynck, C. Netzer, S. Fischer, H. Rode, D. Rauh, J. Rahnenführer and R. K. Thomas: Analysis of compound synergy in high-throughput cellular screens by population-based lifetime modeling. In: PLoS ONE 5, 1, e8919-e8919 (2010).
doi: 10.1371/journal.pone.0008919
Sos, M. L., H. B. Rode, S. Heynck, M. Peifer, F. Fischer, S. Klüter, V. G. Pawar, C. Reuter, J. M. Heuckmann, J. Weiss, L. Ruddigkeit, M. Rabiller, M. Koker, J. R. Simard, M. Getlik, Y. Yuza, T.-H. Chen, H. Greulich, R. K. Thomas and D. Rauh: Chemogenomic profiling provides insights into the limited activity of irreversible EGFR inhibitors in tumor cells expressing the T790M EGFR resistance mutation. In: Cancer Research 70, 3, 868-874 (2010).
doi: 10.1158/0008-5472.CAN-09-3106
Sos, M. L., H. B. Rode, S. Heynck, M. Peifer, F. Fischer, S. Klüter, V. G. Pawar, C. Reuter, J. M. Heuckmann, J. Weiss, L. Ruddigkeit, M. Rabiller, M. Koker, J. R. Simard, M. Getlik, Y. Yuza, T.-H. Chen, H. Greulich, R. K. Thomas and D. Rauh: Chemogenomic Profiling Provides Insights into the Limited Activity of Irreversible EGFR Inhibitors in Tumor Cells Expressing the T790M EGFR Resistance Mutation. In: Cancer Research 70, 3, 868-874, Seq. No.: 1 (2010).
url: http://dx.doi.org/10.1158/0008-5472.CAN-09-3106
Weiss, J., M. L. Sos, D. Seidel, M. Peifer, T. Zander, J. M. Heuckmann, R. T. Ullrich, R. Menon, S. Maier, A. Soltermann, H. Moch, P. Wagener, F. Fischer, S. Heynck, M. Koker, J. Schöttle, F. Leenders, F. Gabler, I. Dabow, S. Querings, L. C. Heukamp, H. Balke-Want, S. Ansén, D. Rauh, I. Baessmann, J. Altmüller, Z. Wainer, M. Conron, G. Wright, P. Russell, B. Solomon, E. Brambilla, C. Brambilla, P. Lorimier, S. Sollberg, O. T. Brustugun, W. Engel-Riedel, C. Ludwig, I. Petersen, J. Sänger, J. Clement, H. Groen, W. Timens, H. Sietsma, E. Thunnissen, E. Smit, D. Heidemann, F. Cappuzzo, C. Ligorio, S. Damiani, M. Hallek, R. Beroukhim, W. Pao, B. Klebl, M. Baumann, R. Buettner, K. Ernestus, E. Stoelben, J. Wolf, P. Nürnberg, S. Perner and R. K. Thomas: Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. In: Science Translational Medicine 2, 62, 62ra93-62ra93 (2010).
doi: 10.1126/scitranslmed.3001451
Weiss, J., M. L. Sos, D. Seidel, M. Peifer, T. Zander, J. M. Heuckmann, R. T. Ullrich, R. Menon, S. Maier, A. Soltermann, H. Moch, P. Wagener, F. Fischer, S. Heynck, M. Koker, J. Schöttle, F. Leenders, F. Gabler, I. Dabow, S. Querings, L. C. Heukamp, H. Balke-Want, S. Ansén, D. Rauh, I. Baessmann, J. Altmüller, Z. Wainer, M. Conron, G. Wright, P. Russell, B. Solomon, E. Brambilla, C. Brambilla, P. Lorimier, S. Sollberg, O. T. Brustugun, W. Engel-Riedel, C. Ludwig, I. Petersen, J. Sänger, J. Clement, H. Groen, W. Timens, H. Sietsma, E. Thunnissen, E. Smit, D. Heidemann, F. Cappuzzo, C. Ligorio, S. Damiani, M. Hallek, R. Beroukhim, W. Pao, B. Klebl, M. Baumann, R. Buettner, K. Ernestus, E. Stoelben, J. Wolf, P. Nürnberg, S. Perner and R. K. Thomas: Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. In: Science Translational Medicine 2, 62, 62ra93-62ra93 (2010).
doi: 10.1126/scitranslmed.3001451
Sos, M. L., S. Fischer, R. Ullrich, M. Peifer, J. M. Heuckmann, M. Koker, S. Heynck, I. Stueckrath, J. Weiss, F. Fischer, K. Michel, A. Goel, L. Regales, K. A. Politi, S. Perera, M. Getlik, L. C. Heukamp, S. Ansen, T. Zander, R. Beroukhim, H. Kashkar, K. M. Shokat, W. R. Sellers, D. Rauh, C. Orr, K. P. Hoeflich, L. Friedman, K.-K. Wong, W. Pao and R. K. Thomas: Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. In: Proceedings of the National Academy of Sciences of the United States of America 106, 18351-18356 (2009).
doi: 10.1073/pnas.0907325106
Sos, M. L., S. Fischer, R. Ullrich, M. Peifer, J. M. Heuckmann, M. Koker, S. Heynck, I. Stückrath, J. Weiss, F. Fischer, K. Michel, A. Goel, L. Regales, K. A. Politi, S. Perera, M. Getlik, L. C. Heukamp, S. Ansén, T. Zander, R. Beroukhim, H. Kashkar, K. M. Shokat, W. R. Sellers, D. Rauh, C. Orr, K. P. Hoeflich, L. Friedman, K.-K. Wong, W. Pao and R. K. Thomas: Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. In: Proceedings of the National Academy of Sciences of the United States of America 106, 43, 18351-18356, Seq. No.: 1 (2009).
url: http://www.pnas.org/content/106/43/18351.abstract
Sos, M. L., S. Fischer, R. Ullrich, M. Peifer, J. M. Heuckmann, M. Koker, S. Heynck, I. Stueckrath, J. Weiss, F. Fischer, K. Michel, A. Goel, L. Regales, K. A. Politi, S. Perera, M. Getlik, L. C. Heukamp, S. Ansen, T. Zander, R. Beroukhim, H. Kashkar, K. M. Shokat, W. R. Sellers, D. Rauh, C. Orr, K. P. Hoeflich, L. Friedman, K.-K. Wong, W. Pao and R. K. Thomas: Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. In: Proceedings of the National Academy of Sciences of the United States of America 106, 18351-18356 (2009).
doi: 10.1073/pnas.0907325106
http://edoc.mpg.de
The Max Planck Society does not take any responsibility for the content of this export.